Tag: rituximab

1. A higher sustained complete remission rate was shown with rituximab treatment compared to mycophenolate mofetil in patients with pemphigus vulgaris. 2. Patients treated with rituximab showed a larger reduction in glucocorticoid use but had more serious adverse events compared to patients treated with mycophenolate mofetil. Evidence Rating Level: 1 (Excellent) Study...
1. Vemurafenib plus rituximab treatment was associated with complete response for refractory or relapsed hairy-cell leukemia patients. 2. Post hoc analysis suggested minimal residual disease negative status and the lack of prior v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors exposure were associated with better survival. Evidence Rating Level: 2...
1. Among patients categorized as B-cell poor group via RNA sequencing, tocilizumab had a significantly higher response rate than rituximab. 2. Likelihood of adverse events and serious adverse events were comparable between both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Rheumatoid arthritis is a chronic autoimmune condition with considerable morbidity...
1. Rituximab was found to significantly reduce median time to remission in new-onset myasthenia gravis. 2. Rituximab appeared to outperform conventional immunosuppressant therapy in terms of need for rescue therapy and adverse effects resulting in discontinuation. Evidence Rating Level: 2 (Good) Myasthenia gravis (MG) is a serious neuromuscular disease, resulting from an autoreactive humoral...
1. In this randomized controlled trial involving patients with antineutrophil cytoplasmic antibody-associated vasculitis in complete remission, administration of rituximab for an additional 18 months was associated with a lower likelihood of relapse versus placebo. 2. Although the vast majority of patients in both groups reported at least 1 adverse event,...